CD47 Knock-out cell line
Invented at Binghamton University
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 157990 |
| Antigen/Gene or Protein Targets | CD47 |
| Parental Line | B16F10 |
| Host | Mouse |
| Tissue | Skin |
| Disease Keywords | melanoma; tumor microenvironment |
| Model | Knock-Out |
| Relevance | CRISPR/Cas9 edited B16F10 cell line designed to help uncover the impact of editing a cell surface protein (CD47), in a tumor microenvironment, and its use as a whole-cell vaccine. |
| Production Details | Cells were cultured in high glucose DMEM and supplemented with 10% v/v Fetal Bovine Serum (FBS) |
| Research Area | Cancer, Cell Signaling & Signal Transduction, Drug Discovery & Development |
| Positive Control | B16F10 parental cells |
| Notes |
CRISPR edited B16F10 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license. |
References: 1 entry
Inducing Tumor Suppressive Microenvironments through Genome Edited CD47 -/- Syngeneic Cell Vaccination
Add a reference
References: 1 entry
Inducing Tumor Suppressive Microenvironments through Genome Edited CD47 -/- Syngeneic Cell Vaccination
Add a reference
